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Brain tumors are one of the most devastating cancers in human with approximately 200 000 
cases reported annually in United States (Khasraw M. & Lassman A.B, 2010). Among all 
types of brain tumors, malignant gliomas are the most frequent subtype of primary brain 
tumors which are categorized into low grade, anaplastic and glioblastoma multiforme 
depending on the histopathological appearance of the tumors. Malignant brain tumors, 
including high grade gliomas and brain metastases of carcinomas, are devastating forms of 
cancer and contribute to a high number of fatalities. According to WHO classification, 
malignant gliomas include grade III and IV tumors with GBM (WHO grade IV), anaplastic 
astrocytoma (WHO grade III), malignant oligodendroglioma (WHO grade III) and 
malignant ependymoma (WHO grade III). 
Current treatment options for malignant brain tumors are surgical resection followed with 
chemotherapy and/or radiotherapy. Despite advances in therapeutic modalities, prognosis 
of the patients remains poor with a mean survival of 14.6 months after diagnosis and a 5-
year survival rate of 9.8% (Wirth T. et al, 2009). Tumor recurrence has been reported to 
usually occur within 12-months after tumor resection. One of the major obstacles to fight 
over tumor recurrence is the highly aggressive and invasive nature of tumors which often 
lead to unsuccessful treatments. Therefore, advancement of therapeutic regimes for treating 
glioma is crucially needed.  
2. Gene therapy for GBM, the history 
Gene therapy is generally defined as a therapeutic approach for correcting defective genes 
by delivering genetic materials into cells. Application of viral vector as the main delivery 
mechanism is consequently called viral gene therapy. Current mostly studied gene therapies 
involve cancers and hereditary diseases via various approaches. The most important aspect 
of gene therapy not only to respond specifically in the target area but also to give favorable 
outcome with the least possible side effects to the patients.  
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Glioma is a perfect target for gene therapy for its dismal prognosis, localized growth in the 
restricted brain areas and absence of metastasis. Advances in gene therapy for brain tumors 
have started long time ago along with other malignant cancers. In 1992, the first clinical trial 
for brain tumors was reported by Brenner et al. They studied the delivery mechanism of IL-2 
gene using retroviral vectors in neuroblastoma patients. Subsequently in the similar year, 
Oldfield et al, Ram et al, and Klatzmann et al have initiate another clinical trial using HSV-tk 
suicide gene therapy approach using Retroviral Vector Producing Cells (VPCs) with intra-
venous Ganciclovir (GCV). (Oldfield et al, 1993 and Ram et al, 1993) 
Currently most utilized gene therapy approaches for brain tumors include suicide gene 
therapy, cytokine gene therapy, oncolytic virotherapy and immune gene therapy with the 
main use of retroviruses, herpes simplex virus and adenoviruses. Malignant gliomas are the 
mostly targeted group for brain tumor gene therapy. The two mainly registered clinical 
trials for brain tumors are cytotoxic gene therapy and suicide gene therapy methods with a 
total numbers of 34 and 32 respectively (Määtta et al, 2009). Along with others, a total of 91 
gene therapy clinical trials have been reported until September 2009 with 62 in phase I, 17 in 
phase I/II, 7 in phase II, 1 in phase II/III and 4 in phase III. 
(www.wiley.co.uk/genetherapy/clinical).  
3. Viral gene therapy/gene delivery vehicles 
Viruses are obligate intra-cellular parasites which generally infecting cells, inserting its DNA 
into the host genome which is eventually transcribed for the purpose of viral replication. 
The virus genome contains the basic information of how to produce more copies of their 
genetic material in order to replicate increase the number of viruses in the host cells. In gene 
therapy approaches, this virus replication nature has been modified by removing the 
sequences necessary for the replication and replacing it with the therapeutic gene of interest. 
The modified virus is subsequently known as viral vector. This modification not only assure 
the production of the target therapeutic genes but also efficiently working without causing 
any harm to the host cells (Kanzawa et al, 2003). 
Gene delivery vehicles consist of viral and non-viral vectors. Viral vectors which are most 
commonly used in gene therapy are described in the following table (Table 1). Non-viral 
vectors used for gene transfer include nucleic acid therapeutics such as antisense 
oligonucleotide and naked DNA plasmid (Kanzawa et al, 2003).    
Delivery mechanism of genetic materials to the patients can be achieved either by direct 
delivery to the cells (in vivo) or by altering the genes of cells outside of the human body and 
transfer it back to the patients (ex vivo). Glioblastoma was the first reported cancer to use in 
vivo technique for gene delivery. (Engelhard H.H., 2005). 
 





• broad cell tropism 
• Stable gene expression due to 
viral genome integration into 
cell chromosomes 
• No toxic effect on infected cells, 
infect only dividing cells 
• Total insert capacity 8 kb 
• Random insertion of viral 
genome, possibility of 
mutagenesis and oncogene 
activation 
• Possibility of replication 
competent virus formation 
• Degraded rapidly by complement 
• Possible recombination with 
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human endogenous retroviruses 
Adenovirus DNA 
virus
• very high titers (1012 pfu/ml) 
• Transiently high levels of gene 
expression 
• Infect both dividing and non-
dividing cells 
• DNA insert capacity 7-8 kb 
• Inflammatory and toxic host 
immune responses 
• Host’s humoral immune 
responses may neutralize 
adenoviral particles 
• Not suitable for long-term 
expression of the transgene 
• Complicated vector genome 
Baculovirus DNA 
virus
• non-human pathogenic 
• Infect dividing and non-
dividing cells 
• Transient or stable transduction
• High transgene capacity  
(>35 kb) 
• Inactivated by complement factor 
• Immunogenicity, elevation of 








• High titers (1010 pfu/ml) 
• Wide range of cells can be 
infected, also non-dividing cells
• Ability o the virus to establish 
latent infection 
• Nonpathogenic, non-toxic, 
small genome 
• Viral integration specific for 
human chromosome 19 
• High titers of pure virus are 
difficult to obtain 
• AAV requires a helper adeno- or 
herpervirus 
• Limited capacity of foreign genes 
• Lack of specific integration for 
recombinant AAV vectors, 
possibly mutagenesis 







• DNA virus, titers range from 
108 to 1010 pfu/ml 
• Does not integrate into the cell 
genome 
• Long-term expression of the 
transgene in neuronal cells 
• Induce cytopathic effects in 
cancer cells 
• Transgene capacity 30 kb 
without affecting neither titers 
nor replication 
• Sensitive to antiherpetic agents 
like ganciclovir, which 
provides a safety mechanism 
by which viral replication could 
be abrogated 
• Host immune responses, 
inflammatory and toxic reactions 
in patients 
• Complicated vector genome 
• Most people have preexisting 
herpes immunity, which could 
mpair gene delivery 
• Ability to infect both replicating 
and nonreplicating cells is 
undesirable for gene therapy 
which requires selective targeting 
of replicating cells 
 
Table 1. Most commonly used viral vectors in gene therapy approaches (Kristiina T. 2006, 
Immonen A. et al, 2004, Kanzawa et al., 2003 and Romano et al, 2000)  
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4. Viral vectors for gene therapy 
Viral vector is the most important vehicle in gene therapy for its efficiency and specificity to 
infect host cells and expressing the transgenes. In gene therapy approach for gliomas, 
retroviruses and adenoviruses have been heavily used in either non-replicating or 
replicating forms in vivo. Additionally, oncolytic viruses such as HSV-1, Measles, New 
Castle Disease Virus (NDV), Reovirus, Poliovirus and Vesicular Stomatitis Virus (VSV) have 
also been tested (Aghi and Chiocca, 2006).  
4.1 Retrovirus (Rv)/lentivirus 
Retrovirus belongs to the family of Retroviridae which is described as RNA type of virus. Rv 
is highly capable of infecting host cells and reverting its RNA to DNA via reverse 
transcriptase activity. The formed DNA is subsequently inserted into host genome before 
being transcribed and translated into protein. (Anson D.S., 2004)   
Retroviral vectors are mostly based upon the Moloney murine leukaemia virus (Mo-MLV), 
an amphotrophic virus which is capable of infecting both mouse cells and human cells thus 
enabling vector development in mouse models and human treatment. 
Rv genome is relatively small (between 8-11 kb) and easy to manipulate for the use of viral 
vector production. It can also be produced in high titers (106-107 pfu/ml) (Romano et al, 
2000). In viral vector development, genome of Rv is modified by replacing the genes 
encoding for gag(capsid), pol(reverse transcriptase) and env(envelope glycoprotein) with 
specific transgene of interest (Kristiina T., 2006). 
In cases of malignant glioma, Rv is known to have a vast advantages as a viral vector for its 
natural activity which is only infecting dividing cells not the non-dividing cells. Therefore, 
the postmitotic non-dividing brain tissue is left unaffected. Rv have also shown stable 
integration of the transgene and leads to long term expression of the target proteins. 
Additionally, Rv demonstrated safety with minimal risk of toxicity in the use of intracranial 
application (Aghi & Chiocca, 2006). However, there are also reported disadvantages 
including relatively low titers of the Rv packaging cells production, and small size genome 
limiting transgene insertion into the cassette. Due to the fact that Rv is integrating into 
dividing cells, there is high risk of insertional mutagenesis and oncogene activation which 
may eventually leading to cancer development. (Kanzawa et al, 2003 and Anson D.S., 2004). 
Lentivirus (Lv) is a subclass of Rv which is considerably more complex than Rv with 
additional six proteins, tat, rev, vpr, vpu, nef & vif. It has been shown that lentivirus can 
infect both dividing and non-dividing cells in a broad range of tissues, stably integrate into 
the host genome and produce long term expression in brain, liver, muscles and retina 
(Miyoshi H. M. et al, 1998).  
4.2 Adenovirus (Ad) 
Adenovirus (Ad) was first isolated from adenoid tissues in 1953 with identification of more 
than 50 serotypes (Russell, 2009 and Volpers & Kochanek, 2004). Adenovirus infection often 
causes illness of respiratory system including acute respiratory infections, pharyngitis and 
conjunctivitis, epidemic keratoconjunctivitis, gastroentitis and pneumonia in young 
children. 
Ad is characterized by non-enveloped type of virus, icosahedral virus with 60-90 nm in 
diameter and having linear double stranded DNA with genome size of 30-40 kb (Volpers & 
Kochanek, 2004). Structure of Ad composed of icosahedral capsid consisting of three major 
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proteins, hexon (II), penton base (III) and knobbed fibre (IV) with some other minor proteins 
which give Ad molecular weight of about 150 MDa (Russell, 2009 and Volpers & Kochanek, 
2004). Ad is capable of accommodating up to 10 kb size of transgene, giving it great 
advantages in gene therapy purposes (King et al, 2008 and Lam & Breakefield, 2001).      
Ad is the most extensively used viral vector in gene therapy clinical trials. Most frequently 
used Ad serotypes in gene therapy are Ad2 and Ad5 (Haritha 2008 and Kristiina T. 2006) 
which are designed as replication defective viruses as generally used in viral vector gene 
therapy (Engelhard H.H., 2000). Therapeutic genes are designed to be inserted in into 
regions of E1A and /or E1B genes, and E2 and E4 genes replacing the original virus 
sequences (Lam & Breakefield, 2001). However, some drawbacks were reported from this 
generation of viruses including, 1) maintenance of the viral genome is rapidly lost in 
dividing cells, 2) viral tumorigenecity, and 3) receptor-mediated uptake of the virus through 
the primary Ad receptor, CAR, whose expression inversely correlates with malignancy 
(Aghi and Chiocca, 2006).     
Ad is capable of infecting various types of quiescent and proliferating cells including lung, 
skeletal muscles, heart, liver, blood cells and central nervous system (Haritha 2008). In gene 
therapy approaches, gene expression from Ad viral vectors occurs without integration of the 
virus into host genome (Kanzawa et al 2003). Additional advantage of Ad viral vectors are 
the ability to be produced in high titers (1012-1013 viral particles per ml) and low 
pathogenicity of the virus. However, Ad viral products have been reported to carry high 
antigenicity and have been associated with toxic and inflammatory responses in brain. 
Additionally, cytotoxic (CTL)-mediated immune respond often leads to clearance of vector 
transduced cells and to short duration of transgene expression (Volpers & Kochanek, 2004 
and Lam & Breakefield, 2001).   
4.3 Other viral vectors 
Herpes Simplex Virus (HSV) is a DNA virus with great advantages for gene therapy 
application. HSV is a common human pathogen which can be found in most people and 
infecting both proliferating and non-proliferating cells (Lam & Breakefield, 2001). Besides 
the ability to replicate in neuronal cells and kill brain tumor cells, HSV has been shown to 
cause fatal encephalitis in humans (Biederer et al, 2002).  
HSV offers great advantages including ability to be produced in high titers (108 to 1010 
pfu/ml), huge size of transgene (up to 30 kb in size) can be inserted into HSV genome 
without affecting the titers or replication, delivery system in CNS is very effective due to 
neurotropism, sensitive to antiherpetic agents like ganciclovir and HSV has been shown not 
to integrate into host genome thus reduce the risk of insertional mutagenesis. However, due 
to its very large viral genome size, the manipulation of the gene becomes more complicated 
in vitro. Additionally, many people have been detected to have pre-existing HSV in their 
body thus provides immunity that could lead to gene delivery failure (Aghi & Chiocca, 2006 
and Romano et al, 2000). Two types of HSV that have been used in clinical trial of glioma 
gene therapy are HSV-G207 and HSV-1716. These two types of viruses are conditionally 
replicating herpes simplex viruses with specific gene mutations and a selective ability to 
replicate only within dividing cancer cells, leading to oncolysis (Haritha, 2008). 
Another type of virus that has shown promising results in glioma gene therapy is adeno-
associated virus (AAV) a type of native human parvovirus. This virus enters the host cells 
by binding to heparin sulfate and able to replicate via assistance of adenovirus or herpes 
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virus. Normally, infection of AAV does not cause any disease in human though integration 
of the virus genome into host genome occurs. The fact that AAV requires help from either 
adenovirus or herpes virus for its replication, gives a clear drawback of this virus in gene 
therapy approach. Additionally, possible transgene that can be inserted into AAV genome is 
too small (5 kbp only) and gene expression may not be so efficient (Kanzawa et al, 2003).   
Other viruses that have been studied in gene therapy for gliomas include Newcastle Disease 
Virus (NDV), Poliovirus, Measles and Vesicular Stomatitis Virus. NDV is an enveloped 
negative-stranded oncolytic RNA (Aghi & Chiocca, 2006) with ability to induce necrosis in 
cancer. Secretion of different cytokines such as interferon and IL-1 may give anti-tumor 
effect in gene therapy application (Biederer et al, 2002). 
Paliovirus is a RNA virus which can specifically infect and replicate in tumor cells due to 
tumor-specific expression of human poliovirus receptor CD 155. Paliovirus does not 
integrate and replicate in postmitotic cells like neurons and has been shown as 
nonpathogenic in primates. In one study, intracranial injection of the poliovirus resulted in 
80% long-term survival at 50 days in immunodeficient mice (Aghi & Chiocca, 2006). 
5. Gene therapy strategies for glioblastoma 
Gene therapy undoubtedly holds a great promise for treating various types of cancer 
including glioblastoma. Currently, we are aware that no single therapeutic will be sufficient 
to eradicate tumor completely. Therefore, the combination of conventional treatments with 
novel gene therapy modalities seems to be the preferred choice (Germano IM., 2009). There 
is a remarkable potential in the rapidly growing gene therapy field for glioblastoma, 
however to many dismay it has not yet been proven to be a success story in terms of 
therapeutic options. There are numerous experimental trials on animal models that hold a 
great promise for malignant glioma treatment (Germano IM., 2009). Nevertheless, in clinical 
practice there are substantial obstacles to be considered. Currently, only several protocols 
were adopted in human studies with varying results. As of June 2010 there were 159 cancer 
gene therapy trials ongoing worldwide, out of which only 13 were targeted against glioma 
(http://clinicaltrials.gov/). The rate limiting steps for successful gene therapy for brain 
tumors lie in the efficiency, stability and safety of viral vectors. However, it is believed that 
the greatest shortcoming comes from the lack of efficiency that is partly caused by the 
treatment execution and delivery methods.  
In this review, gene therapy approaches for gliomas in 4 different categories will be 
discussed; 1) pro-drug activation/suicide gene therapy; 2) transfer of tumor suppressor 
genes and cell cycle modulators;  3) genetic immune modulation; and 4) anti-angiogenic 
gene therapy. 
5.1 Pro-drug activation/suicide gene therapy 
Pro-drug activation which is also known as suicide gene therapy applies the concept of 
delivering a gene encodes for certain enzyme which can metabolize a non-toxic drug to 
become toxic (suicide gene) and subsequently kill the tumor cells.  
5.1.1 Herpes simplex virus type 1/tymidine kinase-ganciclovir (HSV-tk/GCV)   
HSV-tk/GCV is the most commonly used gene therapy approaches for glioma. In this two-
step therapy approach, HSV-tk enzyme converts non-toxic nucleoside analogs, ganciclovir into 
phosphorylated compounds which kills actively dividing cells particularly tumor cells (Aghi 
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& Chiocca, 2006 and Wirth et al, 2009). GCV is a synthetic acyclic analogue of 2’-deoxy-
guanosine, chemically designed as 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine. 
In the pro-drug activation approach, HSV-tk presented a higher capability compared to any 
other mammalian enzymes to phosphorylating GCV and subsequently changes its 
conformation into GCV-monophosphate residue (Määtta et al, 2009 and Wirth T. et al, 2009). 
Further actions by intracellular kinases converts GCV-monophosphate into GCV-triphosphate 
(GCV-TP) which is capable to inhibit DNA polymerase or its incorporation into DNA, 
resulting to DNA chain termination. This mechanism of actions specifically targeting DNA 
replication particularly S-phase-specific, thus giving advantage that only dividing cells or in 
this case only tumor cells are affected (Fueyo J. et al, 1999, Aghi & Chiocca, 2006  and Wirth T. 
et al, 2009).   
The efficiency of this approach also depends very much on the bystander effects of the 
enzyme activities, referring to the killing of cells that are adjacent to the cells transduced 
with HSV-TK/GCV. These cells do not express the enzyme but receive similar effects 
through cell-to-cell contact via gap junctions which allow transfer of Ganciclovir 
triphosphate from HSV-TK+ cells to non-transduced cells. Activation of the enzyme in the 
transduced and adjacent cells allow formation of the cytotoxic molecules which contribute 
to the increment of the treatment efficiency and cells death (Aghi and Chiocca, 2006, 
Kanzawa et al., 2003). 
Gene therapy via HSV-tk approach has undergone clinical trial (phase III) in many countries 
using retrovirus and most recently adenovirus (Kanzawa at al, 2003 and Asadi-Moghaddam 
K. and Chiocca E.A, 2009).  Until September 2008, a total of 34 clinical trials were registered 
worldwide with malignant glioma being the biggest sub-group treated. HSV-tk has been the 
most widely used approach with 32 clinical trials (Maatta et al, 2010).   
5.1.2 CD/5-FC combination 
5-Fluoro Cytosine (5-FC) is an anti-fungal agent that is generally used to treat fungal 
infection (Asadi-Moghaddam K. and Chiocca E.A, 2009). In gene therapy modality, this 
prodrug is converted into active and toxic form of 5-fluorouracil (5-FU) by enzyme called 
cytosine deaminase (CD). The toxic effects of 5-FU is mediated by its intracellular 
metabolites, via conversion of 5-FU onto 5-fluoro-2’-deoxyuridine-5’-monophosphate, 
causes DNA strand breakage leading to cell death (Aghi and Chiocca, 2006).  
It has been shown that tumor cells receiving CD may present CD peptides on the MHC Class I 
which could lead to immune response activation. CD/5-FU combination renders a strong 
bystander effects compared to HSV-tk due to its ability to diffuse via membrane cells and 
enters the nontransduced cells (Lam & Breakefield, 2003). Adenovirus has been used in the 
experimental studies for CD/5-FU combination. There is one registered study which is now in 
the stage of recruiting patients for the Phase I clinical trials (http://clinicaltrials.gov).  
5.1.3 Cytochrome P450 2B1/cyclophosphamide (CPA) 
Another pro-drug activating enzyme that has been well-characterized in gene therapy is rat 
cytochrome P450 2B1/cyclophosphamide (CPA). CPA is a pro-drug agent that can be 
activated by liver-specific enzyme of the cytochrome P450 family via its conversion to 
phosphoramide mustard (PM). PM relatively appears in a stable and diffusible form with 
ability to enter adjacent cells without contact-dependent bystander effects. (Aghi and 
Chiocca, 2006)   
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This approach has initially been developed for the use in brain tumor (Chen L. et al, 1997). 
Studies using retrovirus have shown great promise to reduce glioma formation in mice 
(Manome et al, 1996 and Wei et al, 1995). Additionally, manipulation of replication-
conditional HSV vector has been used for carrying P450 2B1/CPA in glioma treatment 
(Aghi et al, 1999). Manipulated HSV-1 virus carrying P450 gene acts via 3 modes; 1) using 
viral oncolysis; 2) rendering the infected cells to CPA; 3) rendering the infected cells to GCV 
(Asadi-Moghaddam K. and Chiocca E.A, 2009). 
Besides the ability to diffuse via membrane to the neighboring cells, use of cytochrome P450 
also less immunogenic than other suicide gene therapy such as HSV-tk thus provides long 
term drug activation (Karle P. et al, 2001). However, due to the fact that cyclophosphamide’s 
active metabolites can only be generated by liver P450 and these metabolites are poorly 
transported across BBB, there may be some limitation of the use in treating glioma (Aghi 
and Chiocca, 2006). 
5.2 Transfer of p53 tumor suppressor genes  
Various studies have shown that alterations of different oncogenes and tumor suppressor 
genes that control the cycle cycle involved in glioma progression. The alteration may cause 
disruption of normal functions of the genes and lead to the uncontrolled proliferation of 
cancer cells (Garrett, 2001). The reported mechanisms by which could abolish the normal 
functions of the tumor suppressor genes include loss of heterozygosity, methylation, 
cytogenetic aberrations, genetic mutations, gain of autoinhibitory function and 
polymorphism (Zingde, 2001). 
One of the most widely studied is p53 tumor suppressor gene which is generally inactivated 
in 35-60% if human malignant gliomas (Kanzawa et al, 2003). Pre-clinical trials with 
adenovirus mediated p53 gene transfer demonstrated promising results with growth 
inhibition of transplated glioma and prolongation of the survival in the models. Lang et al in 
his phase I clinical trial also reported median survival of the glioma patients was 10 months 
and no-recurrence has been reported in 1 patient for up to 3 years. Lang et al in their studies 
used two-staged approach for delivering the therapeutic genes; adenovirus vector 
containing p53 gene was injected intratumorally via a stereotactically implanted catheter, 
whereafter the tumor and catheter were resected en bloc and re-injections (up to 3 x 1012 vp) 
were performed into the walls of the tumor cavity. (Pulkkanen & Ylä-Herttuala, 2005 and 
Lang et al, 2003)   
There are also reports that p53 gene transfer is not effective to wild type p53 and glioma is a 
mixture of cells with mutated p53 and wild-type p53 resulted to partially effective p53 gene 
therapy. In relation to that, p53 gene therapy combinations have been introduced in order to 
increase the therapeutic effects. For example, p53 in combination with radiation improves 
the positive effects in heterogenous cells (Fueyo J. et al, 1999). Interesting study by Huang et 
al showed that combination therapy of p53 with HSV-tk/GCV suicide gene therapy 
demonstrated a synergistic effect in C6 rat glioma model (Huang et al, 2007). P53 in 
combination with oncolytic virotherapy has improved the survival in animal models 
(Geoerger et al., 2004). 
Other therapeutic genes that hold great promise to glioma gene therapy include epidermal 
growth factor receptor gene, which is often amplified in malignant gliomas (Asadi-
Moghaddam K. and Chiocca E.A, 2009).  
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5.3 Immuno gene therapy  
The concept of immune gene modulation in cancers implies the use of various cytokines to 
enhance the immune response against tumor cells. Most widely studied cytokines in 
malignant gliomas are interleukin IL-2, IL-4, IL-12, interferon (IF)-┚, IF-┛,39 and 
granulocyte-macrophage colony stimulating factor (GM-CSF) (Kanzawa et al, 2003 and Lam 
& Breakefield, 2001).      
Malignant glioma is a great target for immune gene therapy because of its structure that 
consists of blood brain barrier (BBB) and without any drainage system. Immuno gene 
therapy can be achieved either via active or passive strategies. Active immunotherapy 
provides long-term effect immunity via up regulating the immune response. On the other 
hand, passive immunotherapy applies the delivery of immune effectors to achieve 
immediate effect but for short term immunity. Various studies are currently ongoing for 
both active and passive immune gene therapy for glioma (Clarke J. et al, 2010).  
Inductions of cytokines production in gliomas are achieved either by direct cells transplant 
or genetically engineered virus which carries specific transgenes. One of the promising 
immune gene therapy approaches is using EGFRvIII as tumor specific antigen to induce 
immune system to fight against the tumor cells. This study has entered phase 2/3 clinical 
trial with promising results (Yamanaka, 2008).   
Other cytokine that have shown efficacy in experimental animals is IFN- ┙. IFN- ┙ inhibits 
cell cycle progression and induces apoptosis in tumor cells thereby leading to enhanced 
immune system reaction by increasing expression of MHC-1 (King 2005 and Yang 2004). 
IFN- ┙ has shown to regress glioma in animal model when co-delivered with DCs into the 
tumor (Tsugawa 2004).  
5.4 Anti-angiogenic gene therapy 
One of the promising areas to improve the efficiency of the gene therapy is by targeting 
angiogenesis in the gliomas. Increasing evidences have shown that similar to any other solid 
tumors, malignant gliomas require sufficient blood supply to sustain growth and 
glioblastomas have been shown to be the most densely vascularized human tumor (Kunkel 
et al., 2001). Since 1971, the idea of inhibition of angiogenesis has emerged and lead to 
extensive research towards identifying and isolating the regulators of angiogenesis, some of 
which represent therapeutic targets.  
Angiostatin, an internal peptide fragment of plasminogen, has recently been shown to 
potently inhibit endothelial proliferation in vitro and tumor growth in vivo. Animal 
experiments carried out by Griscelli and co-workers (1998) showed decreased tumor 
volume, decreased tumor vascularity and increased tumor cell apoptosis in nude mouse 
model injected with adenovirus expressing angiostatin. Recombinant angiostatin has also 
been reported to inhibit growth and neovascularization of intracerebral glioma xenografts, 
as well as to increase tumor cell apoptosis (Rege et al., 2005).  
Endostatin, a 20-kDa carboxyl-terminal proteolytic cleavage fragment of collagen 18 is also a 
potential angiogenic inhibitor. Endostatin was originally reported to inhibit the proliferation 
of bovine capillary endothelial cells, but not the proliferation of cells of nonendothelial 
origin, and also inhibit angiogenesis in the chick chorioallantoic membrane model. 
However, complete tumor inhibition was not observed in either the athymic or 
immunocompetent animal glioma models (Rege et al., 2005, Kanzawa et al., 2003).  
Despite some failures and ongoing research in finding anti-angiogenic therapies for gliomas, 
some of the researchers are interested with the potential of bevacizumab (avastin) shown in 
non-small-cell-lung cancer, renal cell cancer and metastatic breast cancer. Bevacizumab is 
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anti-VEGF-A which has been approved by the US Food and Drug Administration (FDA) for 
the treatment of metastatic colorectal cancer in combination with 5-fluorouracil (FU)-based 
chemotherapy regimens. Clinical trials of bevacizumab for malignant glioma patients have 
been carried out by some researchers but conclusive data is not yet been published. 
(Vredenburgh J.J., 2007, Rose S.D and Aghi M.K, 2010) 
6. Conclusion 
Advances in the approach of gene therapy for gliomas via pro-drug activation/suicide gene 
therapy, transfer of tumor suppressor genes and cell cycle modulators, genetic immune 
modulation and anti-angiogenic gene therapy have shown great promises to better the 
current treatment regimes. Either being delivered in single or combination with other 
conventional treatment, gene therapy is anticipated to be able to translate the successful 
findings from animal experiments to clinical application. In clinical practice, the challenges 
are not only to fight the extreme invasive and aggressive nature enclosed in malignant 
gliomas, but also to overcome the difficulties of delivering modified virus vectors into the 
solid tumor as well as to ensure the efficiency of the genetic transfer. Currently, gene 
therapy for gliomas is studied in different clinical trials phases. 
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